Allergy Therapeutics (AGY)

 

LSE:AGY: Result of AGM

Allergy Therapeutics

24 Nov 2016 17:23:19

Allergy Therapeutics

RNS Number : 1225Q
Allergy Therapeutics PLC
24 November 2016
 



24 November 2016

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

 

Result of Annual General Meeting

 

 

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, at the Annual General Meeting held yesterday, all the resolutions put to that meeting were duly passed.

 

ENDS

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan

[email protected]

 

Note to editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGFEUFWLFMSEFF